| Milan Zdrnja, MD | |
|
2610 W Horizon Ridge Pkwy, Suite 200, Henderson, NV 89052-2869 | |
| (702) 407-8241 | |
| (702) 492-1728 |
| Full Name | Milan Zdrnja |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 26 Years |
| Location | 2610 W Horizon Ridge Pkwy, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386931004 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 125.055742 (Illinois) | Secondary |
| 207R00000X | Internal Medicine | 14498 (Nevada) | Secondary |
| 208M00000X | Hospitalist | 14498 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Infinity Hospice Care Llc | Las vegas, NV | Hospice |
| Southern Hills Hospital And Medical Center | Las vegas, NV | Hospital |
| Entity Name | Pioneer Health Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588681332 PECOS PAC ID: 3577560457 Enrollment ID: O20061107000417 |
News Archive
Electronic health records uptake in the U.S. has accelerated dramatically as a result of government initiatives and the considerable resources – both capital and time - healthcare providers have invested over the past five years. Electronic health records have become the heart of health IT, and U.S. clinicians use them on a daily basis.
XenoPort, Inc. announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate. Preclinical data on this new product candidate will be presented tomorrow at the National Fragile X Foundation's 12th International Fragile X Conference in Detroit, Michigan.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
Less than one hour of resistance exercise training per week lowers the risk of developing metabolic syndrome (cardiovascular risk factors such as overweight, high blood pressure and elevated blood sugar).
The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today.
› Verified 1 days ago
| Entity Name | Milanz Hospitalist Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417353301 PECOS PAC ID: 2668798737 Enrollment ID: O20150309000136 |
News Archive
Electronic health records uptake in the U.S. has accelerated dramatically as a result of government initiatives and the considerable resources – both capital and time - healthcare providers have invested over the past five years. Electronic health records have become the heart of health IT, and U.S. clinicians use them on a daily basis.
XenoPort, Inc. announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate. Preclinical data on this new product candidate will be presented tomorrow at the National Fragile X Foundation's 12th International Fragile X Conference in Detroit, Michigan.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
Less than one hour of resistance exercise training per week lowers the risk of developing metabolic syndrome (cardiovascular risk factors such as overweight, high blood pressure and elevated blood sugar).
The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Milan Zdrnja, MD 2610 W Horizon Ridge Pkwy, Suite 200, Henderson, NV 89052-2869 Ph: (702) 407-8241 | Milan Zdrnja, MD 2610 W Horizon Ridge Pkwy, Suite 200, Henderson, NV 89052-2869 Ph: (702) 407-8241 |
News Archive
Electronic health records uptake in the U.S. has accelerated dramatically as a result of government initiatives and the considerable resources – both capital and time - healthcare providers have invested over the past five years. Electronic health records have become the heart of health IT, and U.S. clinicians use them on a daily basis.
XenoPort, Inc. announced today that it has discovered a novel prodrug that has the potential to improve significantly the blood concentration of acamprosate compared with the currently approved formulation of acamprosate. Preclinical data on this new product candidate will be presented tomorrow at the National Fragile X Foundation's 12th International Fragile X Conference in Detroit, Michigan.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
Less than one hour of resistance exercise training per week lowers the risk of developing metabolic syndrome (cardiovascular risk factors such as overweight, high blood pressure and elevated blood sugar).
The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today.
› Verified 1 days ago
Mihaela Florescu Missel, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 3001 Saint Rose Pkwy, Henderson, NV 89052 Phone: 702-616-5000 | |
Dr. Diana Dantian Lee, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10624 S Eastern Ave Ste A-955, Henderson, NV 89052 Phone: 702-407-7700 Fax: 702-407-7016 | |
Zachary David Hanson, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10624 S Eastern Ave # A-955, Henderson, NV 89052 Phone: 702-800-5393 | |
Mr. Neel Tapryal, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 10624 S Eastern Ave # A955, Henderson, NV 89052 Phone: 702-800-5393 | |
Michelle Pappy, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10624 S Eastern Ave, Suite A263, Henderson, NV 89052 Phone: 760-628-5368 | |
Dr. Sean Jeet Singh, M.D. Hospitalist Medicare: May Accept Medicare Assignments Practice Location: 170 S Green Valley Pkwy Ste 300, Henderson, NV 89012 Phone: 702-794-1241 | |
Mr. Tabreez Shiraaz Ali, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 28 Brookridge Dr, Henderson, NV 89052 Phone: 702-487-7055 Fax: 702-991-7258 |